Amplia Therapeutics Phase 2a Trial Update

Amplia Therapeutics Limited (ASX:ATX) has announced the successful progress of its Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer. The trial, known as the ACCENT trial, has achieved the required response rate, allowing for the recruitment of the next cohort of 24 patients, bringing the total to 50 patients on study.

Executive Commentary on Trial Progress

Amplia CEO and MD Dr Chris Burns stated, 'Having now confirmed our sixth PR, we will move forward with recruiting the remaining 24 patients for the trial. We are actively working with our clinical sites to ensure seamless reopening of enrolment with the goal of completing recruitment by the end of March 2025. As always, we thank the patients and their loved ones for being involved with this trial.'

Summary of Trial Achievements and Outlook

Amplia Therapeutics' Phase 2a ACCENT trial for advanced pancreatic cancer has shown promising results with six patients achieving the required reduction in tumour size, allowing for the recruitment of additional patients. The trial explores the activity of narmafotinib in combination with standard-of-care chemotherapy and has demonstrated generally well-tolerated treatment with no safety trends identified. The company aims to complete recruitment by the end of Q1 2025 and plans to report a detailed interim analysis of the trial data in the coming weeks. Narmafotinib, the company's FAK inhibitor, has shown promising data in preclinical cancer studies and is currently in an open-label Phase 2a trial. Amplia Therapeutics remains focused on advancing its pipeline of FAK inhibitors for cancer and fibrosis, with a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer.